Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- GLs on Proper Use of Antibacterials Completed
May 14, 2001
- Eisai Ties Up with Neurogenetics
May 14, 2001
- OTC NEWS IN BRIEF
May 14, 2001
- BUSINESS NEWS IN BRIEF -1-
May 14, 2001
- Sumitomo Corp. Establishes Bioventure Investment Fund
May 14, 2001
- DIAGNOSTIC NEWS IN BRIEF
May 14, 2001
- Rohto to Launch Obagi Series of Skin Care Products in Japan
May 14, 2001
- MEDICAL DEVICE NEWS IN BRIEF
May 14, 2001
- WORLD NEWS IN BREF
May 14, 2001
- Japan-EU Mutual GMP Recognition Accord to Be Approved by Diet
May 14, 2001
- 6 New Drugs Including Insulin-lyspro Approved
May 14, 2001
- Chugai Starts V's 21 Plan: President Nagayama
May 14, 2001
- PMSB Proposes NDA Dossier Guide According to CTD
May 14, 2001
- Yamanouchi to Boost Sales to\600 Bil. in FY2005: President Takenaka
May 14, 2001
- REGULATORY NEWS IN BRIEF -1-
May 14, 2001
- Hitachi to Develop New Clinical Data Management System with AstraZeneca
May 14, 2001
- REGULATORY NEWS IN BRIEF -2-
May 14, 2001
- FTC Inspects Tohoku Wholesalers on Suspicion of Price Cartel
May 14, 2001
- Kenporen Predicts 6.6% Increase in Medical Costs for Elderly
May 14, 2001
- JPMA to Prepare for ICH6 in Japan in 2003
May 14, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…